New Market Perspective
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

New Market Perspective

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

by admin June 4, 2025
June 4, 2025
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
5 Biggest Blockchain ETFs in 2025
next post
Massive Russia sanctions package stalls as Trump pushes for Ukraine peace talks

Related Posts

Quimbaya Gold Closes Third Tranche and Upsizes Private...

February 14, 2025

​Tech 5: Stocks Rise as Inflation Cools, Google...

August 19, 2024

Alvopetro Announces Annual Long-term Incentive Grants

November 16, 2024

CWENCH Hydration Strengthens its Retail Footprint in Western...

February 4, 2025

Empire Metals Limited Announces Conference Presentations in Australia...

May 3, 2025

NORTH ARROW AND SPRINGBOK AGREE TO DIAMOND ROYALTY...

February 6, 2024

Germany, Italy Face Pressure to Repatriate US$245 Billion...

June 25, 2025

Radiopharm Theranostics Targets Nasdaq Listing by End of...

July 26, 2024

John Ciampaglia: Gold’s “Extreme” Run — Price Drivers...

April 29, 2025

Widespread Natural Rutile Observed Throughout the Central Rutile...

June 11, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Obama-era officials mum on allegations of ‘manufactured’ intelligence launching Trump-Russia probe

      July 22, 2025

    • Hunter Biden special counsel got ‘one resume’ from DOJ to help prosecute president’s son

      July 22, 2025

    • Iran will not give up nuclear enrichment, top official confirms in exclusive Fox News interview

      July 22, 2025

    • AOC slams progressive critics for ‘lying’ about her Iron Dome stance in defense bill fight

      July 22, 2025

    • ‘All the options’: GOP eyes cutting August recess to move dozens of Trump nominees stalled by Dems

      July 22, 2025

    • Federal judge blocks Trump administration from defunding some Planned Parenthood facilities

      July 22, 2025

    Popular

    • 1

      Top 5 Junior Copper Stocks on the TSXV in 2023

      December 22, 2023
    • 2

      Crypto Market 2023 Year-End Review

      December 22, 2023
    • 3

      Canada Silver Cobalt Begins Drilling at Lowney-Lac Edouard in Quebec, Targeting Nickel-Copper-Cobalt Mineralization

      December 22, 2023
    • 4

      10 Top Oil-producing Countries (Updated 2024)

      October 19, 2024
    • 5

      Powered by rain, this seed carrier could help reforest the most remote areas

      December 19, 2023
    • 6

      A troubling theory about traders profiting from Hamas’ attack on Israel drew much attention. Why it may not be so simple.

      December 13, 2023
    • 7

      Top 10 Uranium-producing Countries (Updated 2024)

      April 18, 2024

    Categories

    • Business (1,416)
    • Investing (3,572)
    • Politics (4,660)
    • World (4,461)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: newmarketperspective.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 newmarketperspective.com | All Rights Reserved